BRIEF published on 09/18/2024 at 07:05, 2 years ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 2 years ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 2 years ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 2 years ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 2 years ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 2 years ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 2 years 1 month ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 2 years 1 month ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 2 years 2 months ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 2 years 2 months ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 09/22/2026 at 14:00, 17 minutes ago GameSquare and Chartis Announce Strategic Data Partnership to Measure Brand and Creator Impact for User-Generated Content (UGC) Across Gaming
Published on 09/22/2026 at 14:00, 17 minutes ago 374Water to Present New Supercritical Water Oxidation Destruction Data at WEFTEC 2026
Published on 09/22/2026 at 14:00, 17 minutes ago NuRAN Wireless to Pilot Starlink LEO Satellite Backhaul for Rural 4G Expansion and Edge AI Enablement
Published on 09/22/2026 at 13:45, 32 minutes ago Galway Metals Announces $14 Million Brokered Private Placement Led by Michael Gentile
Published on 09/22/2026 at 13:30, 47 minutes ago Silver X Increases Measured and Indicated Resources 173% to 10.4 Mt at 213 g/t AgEq (70.8 Moz AgEq) and Inferred Resources 43% to 21.6 Mt at 252 g/t AgEq (180.9 Moz AgEq)
Published on 09/22/2026 at 14:05, 12 minutes ago Claros Technologies Announces Continued Commercial Expansion into Europe and Entry into Pharmaceutical Manufacturing with a Successful PFAS Destruction Pilot at Bachem AG
Published on 09/22/2026 at 14:02, 15 minutes ago Biocon's Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach
Published on 09/22/2026 at 14:02, 15 minutes ago OSCP open-sources a ROS 2 driver for its MK2 inertial measurement units
Published on 09/22/2026 at 13:23, 53 minutes ago Custodian Property Income REIT plc: Interim dividend
Published on 09/21/2026 at 18:19, 19 hours 58 minutes ago Reporting on share buyback transactions carried out between September 14 and September 18, 2026
Published on 09/21/2026 at 18:01, 20 hours 16 minutes ago Partnership agreement signed between Manitou Group and HD Construction Equipment
Published on 09/21/2026 at 17:46, 20 hours 31 minutes ago WEB SA - STATUTORY HALF-YEAR RESULTS AS OF 30/06/2026
Published on 09/21/2026 at 07:00, 1 day 7 hours ago Peugeot Invest takes a stake in Mérieux NutriSciences
